Evidence map›Paper›PMID 24076549›Full record

ArticleBone marrow transplantation2014

Risk factors and organ involvement of chronic GVHD in Japan.

J Kanda, H Nakasone, Y Atsuta, T Toubai, H Yokoyama, T Fukuda, S Taniguchi, K Ohashi, H Ogawa, T Eto and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Neoself Antigens Presented on MHC Class II Molecules in Autoimmune Diseases.Advances in experimental medicine and biology · 2024
    Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

J KandaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
H NakasoneDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Y AtsutaDepartment of Hematopoietic Stem Cell Transplantation Data Management/Biostatistics, Nagoya University School of Medicine, Nagoya, Japan.
T ToubaiDivision of Hematology & Oncology, Department of Internal Medicine, University of Michigan Cancer Center, Ann Arbor, MI, USA.
H YokoyamaDivision of Clinical Oncology and Hematology, Jikei University School of Medicine, Tokyo, Japan.
T FukudaStem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
S TaniguchiDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
K OhashiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
H OgawaDivision of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.
T EtoDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
K MiyamuraDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Y MorishimaDivision of Epidemiology and Prevention, Aichi Cancer Center, Nagoya, Japan.
T Nagamura-InoueDepartment of Cell Processing & Transfusion, Research Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
H SakamakiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
M MurataDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Few studies have evaluated the risk factors for chronic GVHD and organ involvement associated with different graft types, including unrelated cord blood (U-CB). We retrospectively studied 4818 adult patients who received their first allogeneic transplantation and survived for at least 100 days. The incidence of chronic GVHD at 2 years was 37%. The following factors were associated with the development of chronic GVHD: female donor/male recipient, CMV-Ab seropositivity, matched related peripheral blood grafts vs matched related BM grafts, no in vivo T-cell depletion and the occurrence of grade II-IV acute GVHD. Among these factors, the association with acute GVHD occurrence was consistently significant across donor subtypes. The use of U-CB was not associated with chronic GVHD, but was associated with a low incidence of extensive chronic GVHD. Chronic GVHD patients who had received U-CB transplants showed less frequent involvement of the oral cavity (28% vs 55%), eye (12% vs 26%), liver (20% vs 44%), lung (11% vs 25%) and joint (0% vs 6%) than those with matched related BM grafts. In conclusion, we found that U-CB transplants were associated with a low incidence of extensive chronic GVHD and less frequent involvement of the oral cavity, eye, liver, lung and joints.

Indexed as

AdolescentAdultAgedChronic DiseaseCord Blood Stem Cell TransplantationFemaleGraft vs Host DiseaseHumansJapanMaleMiddle AgedRisk FactorsTransplantation, HomologousUnrelated DonorsYoung Adult

Identifiers

PMID24076549

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.